lilly retatrutide trial Lilly's triple agonist delivers up to 71.2 lbs of weight loss Retatrutide, Eli Lilly's next obesity

Description

Cornier MA

Weight loss itself can shift thyroid hormone requirementsas body composition changes, the volume of distribution for thyroid medications shrinks, potentially causing hormone levels to rise

In UK practice, code the clinical manifestation first (e.g., R11.0 for nausea), followed by Y42.3 (Insulin and oral hypoglycaemic drugs causing adverse effects in therapeutic use) as the secondary external cause code

This approach ensures that GLP-1 therapy is tailored to those most likely to benefit from improved metabolic health, weight reduction, and reduced risk of other health conditions such as cardiovascular issues and blood sugar imbalances